Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
PALI

PALISADE BIO (PALI) stock: insider trades, news & valuation

Health Care · Net buying
Close · Oct 9, 2026 $1.54 +6.2% on the day -26.7% over 12 months 52-week range $1.35 – $2.80

Share price and insider trades

PALI closeInsider buyInsider sale
1.001.502.002.503.00NovDecJan 2026FebMarAprMayJunJulAugSepOctBought $8,350 on 2026-01-16 · Donald Allen WilliamsBought $9,400 on 2026-01-09 · Donald Allen WilliamsSold $10,299 on 2026-02-12 · John David Finley, Mitchell Lawrence JonesBought $14,200 on 2026-10-01 · Donald Allen WilliamsBought $14,600 on 2026-10-02 · Donald Allen WilliamsBought $19,800 on 2026-07-02 · Robert Baltera Jr.Bought $39,600 on 2026-07-01 · Robert Baltera Jr.Bought $39,800 on 2026-07-08 · Robert Baltera Jr.Bought $41,000 on 2026-07-06 · Robert Baltera Jr.Bought $49,000 on 2026-07-09 · Robert Baltera Jr.Bought $60,900 on 2026-07-07 · Robert Baltera Jr.Sold $410,226 on 2026-07-07 · John David Finley, Mitchell Lawrence Jones
Bought, 12 months$279K
Sold, 12 months$421K
Insiders buying2
Insiders selling2

PALISADE BIO insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $279K and 2 sold $421K of PALI stock on the open market; P/E 2.6 vs. a sector median of 24.7.

PALI insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q1 2026: $18K bought (2 trades)$18KQ1 2026: $10K sold (2 trades)Q1 2026Q2 2026Q3 2026: $250K bought (6 trades)$250KQ3 2026: $410K sold (2 trades)Q3 2026Q4 2026: $29K bought (2 trades)$29KQ4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026$29K2—0
Q3 2026$250K6$410K2
Q2 2026—0—0
Q1 2026$18K2$10K2

Valuation, profit and volume

P/E (trailing)2.6Sector median 24.7
Market value$268MBiotechnology
Profit margin0.0%Revenue growth —
Volume vs. 50-day0.7×Last 5 sessions
Insiders' paper profit−$58KOn all tracked purchases -19.5%

Summary

Over the past 12 months, 2 PALISADE BIO, INC. insiders reported open-market purchases totaling $279K, while 2 insiders reported sales totaling $421K. Among insiders with enough purchase history to measure, Robert Baltera Jr. (Director) has the highest Insider Score at 7. 0 of 4 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

PALI stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Oct 5SEC Donald Allen WilliamsDirector Buy 10,0001,590,294 held (+1%) $1.46 $15K +5.5% —
Oct 5SEC Donald Allen WilliamsDirector Buy 10,0001,580,294 held (+1%) $1.42 $14K +8.5% —
Jul 10SEC Robert Baltera Jr.Director Buy 25,000461,904 held (+6%) $1.96 $49K -21.4% 7
Jul 10SEC Robert Baltera Jr.Director Buy 20,000436,904 held (+5%) $1.99 $40K -22.6% 7
Jul 8SEC John David FinleyCEO, CFO Sell 146,798217,555 held (−40%) $2.07 $304K -25.6% —
Jul 8SEC Mitchell Lawrence JonesChief Medical Officer Sell 51,88094,009 held (−36%) $2.05 $106K -24.9% —
Jul 8SEC Robert Baltera Jr.Director Buy 30,000416,904 held (+8%) $2.03 $61K -24.1% 7
Jul 8SEC Robert Baltera Jr.Director Buy 20,000386,904 held (+5%) $2.05 $41K -24.9% 7
Jul 6SEC Robert Baltera Jr.Director Buy 20,000356,904 held (+6%) $1.98 $40K -22.2% 7
Jul 6SEC Robert Baltera Jr.Director Buy 10,000366,904 held (+3%) $1.98 $20K -22.2% 7
Feb 13SEC John David FinleyCEO, CFO Sell 3,89627,353 held (−12%) $1.75 $7K -12.0% —
Feb 13SEC Mitchell Lawrence JonesChief Medical Officer Sell 1,98913,263 held (−13%) $1.75 $3K -12.0% —
Jan 21SEC Donald Allen WilliamsDirector Buy 5,00010,728 held (+87%) $1.67 $8K -7.8% —
Jan 13SEC Donald Allen WilliamsDirector Buy 5,0005,728 held (+687%) $1.88 $9K -18.1% —

Insiders at PALISADE BIO, INC.

InsiderBoughtSoldLast filingScore
Robert Baltera Jr.Director $250K — Jul 10, 2026 7
John David FinleyCEO, CFO — $311K Jul 8, 2026 —
Donald Allen WilliamsDirector $47K — Oct 5, 2026 —
Mitchell Lawrence JonesChief Medical Officer — $110K Jul 8, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

PALI stock: common questions

Are PALISADE BIO, INC. insiders buying PALI stock?

In the past 12 months, 2 insiders reported open-market purchases of PALI worth $279K. The latest was Director Donald Allen Williams bought $15K of PALI at $1.46.

Are PALISADE BIO, INC. insiders selling PALI stock?

2 insiders reported sales worth $421K over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is PALI's P/E ratio?

PALI trades at about 2.6 times trailing earnings, compared with a median of 24.7 for the Health Care sector.

What is PALI's 52-week range?

Over the past year PALI has traded between $1.35 and $2.80. It last closed at $1.54 on Oct 9, 2026.